Biogen (BIIB) Peer Comparison
$217.03
$-4.47
(-2.02%)
As on 28-Aug-2026 13:33EDT
Market cap
$31,671 Mln
Revenue (TTM)
$9,948 Mln
P/E Ratio
39.4
P/B Ratio
1.7
Div. Yield
0 %
Edit
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
31,671 | 1,109,683 | 644,335 | 462,684 | 367,584 |
Revenue ($ Mln) |
9,948 | 79,666 | 97,929 | 64,386 | 66,400 |
Net Profit ($ Mln) |
835.09 | 26,709.50 | 21,037.00 | 6,314.00 | 3,173.00 |
Net Margin (%) |
8.39 | 33.53 | 21.48 | 9.81 | 4.78 |
RoE (%) |
4.50 | 88.42 | 25.27 | -- | 6.72 |
Price to Earnings |
39.40 | 42.93 | 31.75 | 75.24 | 122.12 |
Price-To-Book |
1.68 | 33.69 | 7.75 | 50.46 | 8.95 |
Income Statement ($ Mln)
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
9,947.90 | 79,665.80 | 97,929.00 | 64,386.00 | 66,400.00 |
|
Cost of Revenue
|
3,212.50 | 12,737.00 | 28,936.00 | 18,365.00 | 16,350.00 |
|
Gross Profit
|
6,913.60 | 54,615.00 | 68,558.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
5,463.10 | 31,939.40 | 42,737.00 | 27,142.00 | 38,994.00 |
|
Operating Profit (EBIT)
|
1,272.30 | 34,989.40 | 26,256.00 | 18,879.00 | 11,056.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
856.40 | 33,594.40 | 25,196.00 | 8,699.00 | 5,948.00 |
|
Provision for Tax
|
21.31 | 6,884.90 | 4,159.00 | 2,383.00 | 2,779.00 |
|
Profit after Tax (Net Income)
|
835.09 | 26,709.50 | 21,037.00 | 6,314.00 | 3,173.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Consolidated Profit
|
0.00 | 12,218.50 | 10,268.00 | 0.00 | 8,748.00 |
Liabilities ($ Mln)
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
18,848.00 | 33,879.00 | 84,971.00 | -5,935.00 | 41,933.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Non-Current Liabilities
|
9,321.50 | 60,663.00 | 61,195.00 | 99,361.00 | 60,087.00 |
|
Current Liabilities
|
3,917.10 | 47,741.00 | 54,895.00 | 41,642.00 | 27,731.00 |
|
Total Liabilities
|
29,439.50 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
24,780.90 | 77,611.00 | 141,286.00 | 101,446.00 | 93,123.00 |
|
Current Assets
|
7,305.70 | 64,672.00 | 59,774.00 | 33,669.00 | 36,679.00 |
|
Total Assets
|
29,439.50 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
8,355.10 | 54,908.00 | 49,036.00 | 70,822.00 | 53,906.00 |
|
Net Current Assets
|
3,388.60 | 16,931.00 | 4,879.00 | -7,973.00 | 8,948.00 |
Cashflow ($ Mln)
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2,204.60 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-1,371.10 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-301.90 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
5.33 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
4.50 | 88.42 | 25.27 | 6,214.71 | 6.72 |
|
ROA (%)
|
2.47 | 16.19 | 8.36 | 3.57 | 2.11 |
|
EBIT Margin (%)
|
11.19 | 31.17 | 26.53 | 20.68 | 10.86 |
|
Net Margin (%)
|
8.39 | 33.53 | 21.48 | 9.81 | 4.78 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.49 | 49.58 | 8.06 | 10.39 | 4.24 |
|
EBIT Growth (%)
|
-57.79 | 39.73 | -7.83 | 125.97 | -64.72 |
|
Net Profit Growth (%)
|
-45.44 | 93.55 | -7.17 | 67.79 | -80.66 |
|
EPS Growth (%)
|
-46.13 | 94.62 | -7.72 | 67.77 | -80.70 |
|
Book Value Growth (%)
|
4.87 | 86.67 | 7.35 | -4,203.16 | -12.99 |
Valuation Ratios
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
19.96 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
1.41 | 36.37 | 6.19 | -125.57 | 4.98 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
9.34 | 35.81 | 12.97 | 26.61 | 10.54 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.39 | 1.41 | 0.44 | -10.53 | 1.22 |
|
Short term debt to equity ratio
|
0.04 | 0.21 | 0.14 | -1.41 | 0.07 |
|
Current Ratio
|
1.87 | 1.35 | 1.09 | 0.81 | 1.32 |
|
Quick Ratio
|
1.26 | 1.00 | 0.81 | 0.69 | 1.10 |
|
Interest Coverage
|
4.01 | 35.29 | 25.90 | 3.98 | 4.41 |
Operating Efficiency Ratios
| Biogen (BIIB) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.95 | 29.47 | 19.45 | 21.47 | 18.92 |
|
Asset Turnover
|
0.29 | 0.48 | 0.39 | 0.36 | 0.44 |
|
Receivable days
|
69.54 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
291.78 | 368.80 | 189.75 | 91.61 | 128.14 |
|
Payable days
|
53.97 | 148.80 | 158.88 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
307.35 | 313.66 | 100.87 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
